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Abstract
Background: Tumor necrosis factor (TNF) is an important cytokine in the pathogenesis of inflammatory bowel disease (IBD).
Anti-TNF antibodies have been successfully implemented in IBD therapy, however their efficacies differ among IBD patients.
Here we investigate the influence of CD64 Fc receptor on the inhibitory activity of anti-TNFs in cells of intestinal wall.
Methods: Intestinal cell lines, monocytes/macrophages and peripheral blood mononuclear cells (PBMCs) were used as
models. The efficacies of adalimumab, infliximab and certolizumab-pegol were assessed by RT-PCR for target genes. Protein
levels and localizations were examined by Western blotting and immunofluorescence. Antibody fragments were obtained
by proteolytic digestion, immunoprecipitation and protein chip analysis. Knock-down of specific gene expression was
performed using siRNAs.
Results: Infliximab had limited efficacy towards soluble TNF in cell types expressing Fc gamma receptor CD64. Both
adalimumab and infliximab had lower efficacies in PBMCs of IBD patients, which express elevated levels of CD64. Infliximab-
TNF complexes were more potent in activating CD64 in THP-1 cells than adalimumab, which was accompanied by distinct
phospho-tyrosine signals. Blocking Fc parts and isolation of Fab fragments of infliximab improved its efficacy. IFN-c-induced
expression of CD64 correlated with a loss of efficacy of infliximab, whereas reduction of CD64 expression by either siRNA or
PMA treatment improved inhibitory activity of this drug. Colonic mRNA expression levels of CD64 and other Fc gamma
receptors were significantly increased in the inflamed tissues of infliximab non-responders.
Conclusions: CD64 modulates the efficacy of infliximab both in vitro and ex vivo, whereas the presence of this receptor has
no impact on the inhibitory activity of certolizumab-pegol, which lacks Fc fragment. These data could be helpful in both
predicting and evaluating the outcome of anti-TNF therapy in IBD patients with elevated systemic and local levels of Fc
receptors.
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Introduction
Inflammatory bowel disease (IBD) is a chronic, relapsing/
remitting inflammatory condition of the gastrointestinal tract,
which can be subdivided into two types: Crohn’s disease (CD) and
ulcerative colitis (UC). Although many pro-inflammatory cytokines
have been implicated in the pathology of IBD, one of them,
namely tumor necrosis factor (TNF), plays a pivotal role in the
course of the disease [1]. TNF is synthesized as a 26 kDa
precursor, known as membrane-bound TNF (mTNF). Soluble
TNF is produced by proteolysis of mTNF mediated by TNF-alpha
converting enzyme (TACE), which resides at the plasma
membrane [2]. Both soluble and membrane TNFs can bind to
either of the two TNF receptors (TNFR1 or TNFR2), triggering a
cascade of intracellular signaling leading to the activation of two
major transcription factors involved in pro-inflammatory response:
NF-kB and AP-1. Consequently, TNF-stimulated cells produce
and secrete a subset of pro-inflammatory cytokines, such as IL-1b,
IL-8 and TNF, which further relay the cascade of inflammation in
surrounding extracellular environment [3]. Additionally, the
effects of TNF include induction of apoptosis, fibrosis, and
migration of immune cells.
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Based on the crucial role of TNF in inflammation, it was
assumed that anti-TNF therapy would be potentially beneficial in
chronic inflammatory conditions such as IBD [4] or rheumatic
diseases [5]. Currently, there are three anti-TNF therapeutics
approved for clinical use: chimeric mouse/human monoclonal
anti-TNF IgG1 antibody (infliximab; IFX), humanized monoclo-
nal anti-TNF IgG1 antibody (adalimumab; ADA) and pegylated
humanized anti-TNF Fab9 fragment (certolizumab-pegol; CZP).
Until now, numerous in vitro models have been employed in order
to study the efficacy of these drugs. Most of those studies focus on
the comparison between different anti-TNFs using single type of
assays or overexpression systems. However, what is lacking so far is
the comparison between different cell types potentially targeted by
TNF at the site of inflammation. In addition to the classical TNF
neutralizing effect, anti-TNF agents are also capable of inducing
mTNF-dependent signaling [6–8], complement-dependent cyto-
toxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC)
and induction of apoptosis in monocytes [9–11]. It has been
reported that all three drugs exhibit nearly similar binding
affinities towards TNF [12]. The outcome of anti-TNF therapy
may also result from other molecular mechanisms, such as
inhibition of apoptosis [13]. It may be that at the sites of
inflammation several different mechanisms operate simultaneous-
ly.
Interestingly, it has been reported that anti-TNF therapeutics
bind to Fc receptors in an Fc fragment-dependent manner [14]. In
line with these findings, it has been recently demonstrated that
anti-TNF agents modulate regulatory functions of immune cells
via their Fc region [15] and that IFX can induce wound healing by
activating regulatory macrophages [16]. However, on one hand,
these studies lack an insight into functional consequences of these
drugs for neutralizing soluble TNF, and on the other, did not
investigate the involvement of other cell types important for the
pathophysiology of IBD. Until now, there are no reports
describing consequences of activation of Fc receptors and their
downstream signaling by anti-TNF therapeutics, despite the fact
that such interactions have been implicated as an important
component of the immunological and therapeutic responses [17–
19].
Here, we report that binding of infliximab to CD64 modulates
its inhibitory activity in different cell types of intestinal wall and
that this has consequences for the infliximab therapy outcome in
IBD patients.
Results
Infliximab exhibits limited inhibitory capacity in blocking
TNF-mediated inflammatory responses in cells
expressing low and high affinity Fc receptors
To test whether the inhibitory efficacy of anti-TNF therapeutics
towards soluble TNF depends on the presence of Fc receptors, we
first screened different cell types of intestinal wall for the presence
of Fc receptors. Both intestine-derived fibroblasts and monocytes/
macrophages expressed detectable amounts of CD64 and CD16
(Figure 1A). Neonatal Fc receptor (FcRn) was detected only in
epithelial cells and fibroblasts. Because the expression of Fc
receptors in fibroblasts is induced upon human cytomegalovirus
(CMV) infection [20], we tested intestinal fibroblasts for the
presence of viral DNA polymerase. As expected, both cell lines
were CMV-positive, as indicated by the specific PCR product
(Figure S1). Consistent with immunoblots, we detected CD64 in
the nuclear envelope and on the cell surface (Figure 1B, arrows),
which is in agreement with previously published observations [21].
Before testing the inhibitory efficacy of IFX and other anti-TNFs,
we determined optimal conditions for the soluble TNF-mediated
inflammatory responses in the cell lines under study (Figure S2).
All responses were specific regarding both signaling pathways and
transcription factor activation (Figure S3). After optimizing
experimental conditions, we tested the inhibitory efficacy of anti-
TNF therapeutic in cell culture. Interestingly, in intestinal
fibroblasts, IFX had limited inhibitory efficiency, whereas both
ADA and CZP fully blocked TNF-mediated response (Figure 1C).
All three drugs efficiently prevented soluble TNF-mediated
response in intestinal epithelial cell line Caco2BBE (Figure 1D),
which expressed neither CD16 nor CD64. A similar correlation
between limited inhibitory capacity of IFX and the presence of
CD64 was observed in THP-1 cells (Figure 1E). In concert with
these findings, we observed that in fibroblastic cell lines from CD
fistulizing patients (F188, F148 and F141), which express high
amounts of both CD64 and CD16, IFX also had limited efficacy
(Figure S4). Limited inhibitory efficacy towards soluble TNF was
also observed when another humanized anti-TNF IgG1, golimu-
mab, was tested in both fibroblasts and monocytic THP-1 cells,
but consistently with previous observations for other anti-TNFs,
not in Caco2BBE cells (Figure S5).
Anti-TNF therapeutic antibodies have limited efficacy in
blocking soluble TNF-mediated responses in peripheral
blood mononuclear cells (PBMCs)
To investigate the role of Fc receptors in modulating the
inhibitory efficacy of anti-TNFs in the setting more closely
resembling in vivo situation, we next tested these compounds ex
vivo in peripheral blood obtained from healthy donors and IBD
patients (Table S1). PBMCs express high levels of all Fc gamma
receptors (Figure 2A–C), including low affinity Fc receptors CD16
and CD32, which are not expressed in THP-1 cells. We observed
that PBMCs from IBD patients who initially did not respond to
IFX therapy displayed significantly higher levels of CD64 and
slightly elevated levels of both CD32 and CD16 as compared to
healthy individuals, which was partially supportive to the
observations reported earlier [22]. Interestingly, as compared
healthy donors, both ADA and IFX had clearly limited efficacies
in blocking TNF-mediated responses in blood of IBD patients as
measured by elevated production of ICAM-1, TNF and IL-8
mRNAs (Figure 2D–F) as well as release of IL-8 in serum
(Figure 2G). Interestingly, ADA, which was initially effective in
THP-1 cells, induced pro-inflammatory responses in PBMCs
when incubated with TNF. Strikingly, certolizumab-pegol, which
lacks an Fc fragment, was completely effective, suggesting the
involvement of Fc receptors/fragments in the observed induction
of pro-inflammatory responses.
IFX-TNF complexes activate Fc receptors and induce the
expression of inflammatory targets via unique tyrosine
phosphorylation signaling
In order to get more insight into possible molecular mecha-
nism(s), which could contribute to the observed differences
between ADA and IFX, we next investigated the activation of
Fc receptors in a setting where anti-TNF IgGs and TNF were pre-
incubated to form immune complexes prior addition to the cell
cultures. Interestingly, we observed that ADA, either alone or in
complex with TNF, was more potent in inducing phospho-tyrosine
signals than IFX (Figure 3A), suggesting stronger Fc receptor
binding and activation. Strikingly, IFX, either alone or in complex
with TNF, was able to trigger phosphorylation of different tyrosine
residues than ADA-TNF complexes as indicated by the appear-
ance of additional bands (Figure 3A, enlarged insert). These signals
Anti-TNFs in Inflammatory Bowel Disease
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were propagated to induce the transcription of target genes
typically associated with responses triggered by IgGs, such as GM-
CSF, MCP-1 and IL-8 (Figure 3B–G), which is consistent with the
observations reported elsewhere [23–25]. Interestingly, binding of
IFX-TNF complexes to CD64 on the surface of THP-1 cells
triggered also the induction of IL-8, which explains at least
partially, why IFX did not completely attenuate TNF-induced
expression of this target gene (Figure 1D).
Blocking Fc receptors with IgG1 molecules prevents
activation of Fc receptors by infliximab and partially
restores its efficacy
In order to investigate whether binding to Fc receptors can
indeed influence the inhibitory efficacy of infliximab, we pre-
incubated the cells with human serum containing high amounts of
IgGs prior to stimulation with anti-TNF therapeutics. As expected,
human serum improved the efficacy of infliximab in case of both
fibroblasts and THP-1 cells (Figure S6), but the extent of this effect
was surprisingly low, which could possibly be explained by
unwanted interactions with other serum components and/or the
influence of other immunoglobulin (sub)classes present in serum.
In order to avoid this, we performed a similar experiment
exclusively in the presence of IgG1 isotype (Figure 4). Interestingly,
although the recovery of efficacy was only 13% in case of CCD-
18Co fibroblasts (Figure 4A and B), the effects of IgG1 in case of
Ko77 fibroblasts and THP-1 cells were more pronounced
(Figure 4C–F).
Figure 1. The presence of Fc receptors has a negative effect on the inhibitory efficacy of infliximab. Different cell types composing
intestinal wall were examined for the presence of Fc gamma receptors. Villin and a-SMA were used to confirm cell type-specific phenotypes (A).
Immunofluorescence analysis of CD64-expressing CCD-18Co fibroblasts. Cells expressing CD64 at the plasma membrane are indicated by arrows. Size
bar: 50 mm (B). Intestinal fibroblasts CCD-18Co (C), intestinal epithelial cells Caco2BBE (D) and THP-1 cells (E) were pre-incubated with anti-TNF
therapeutics, and subsequently treated with human recombinant TNF to induce pro-inflammatory response. Values on Y axis represent mRNA
expression levels relative to ß-actin. Columns represent mean values of four independent experiments measured in triplicate. Error bars represent SD.
*p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0043361.g001
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Fc and Fab fragments of infliximab contribute differently
to its inhibitory activity in intestinal fibroblasts and
monocytic THP-1 cells
In order to verify the role of Fc part of infliximab in limitation of
its efficacy, we blocked the Fc fragments using protein A sepharose
beads. To test the binding of anti-TNF antibodies to protein A
sepharose beads, we employed standard SDS-PAGE/Coomassie
approach (Figure S7,A). Once the optimal binding conditions were
established, we blocked the Fc regions of both ADA and IFX by
protein A sepharose beads and performed cell treatments using
CD64-expressing CCD-18Co fibroblasts. Interestingly, blocking
Fc fragments inflicted different effects on the inhibitory efficacy of
both anti-TNFs IgGs: adalimumab partially lost its inhibitory
potential, while infliximab’s efficiency significantly improved
(Figure 5A). In order to investigate the involvement of Fab
fragments, we employed a protocol of proteolytic digestion where
both Fab and Fc fragments were separated after 60 min of
digestion with IdeS (Figure S7,B) and Fc fragments were removed
from the reaction mixture using protein A sepharose beads (Figure
S7,C). Interestingly, when isolated Fab fragments were used to
block TNF-mediated responses in THP-1 cells, we found
statistically significant recovery in case of infliximab and 6%
loss-of-activity in case of adalimumab (Figure 5B). When the same
experiment was performed using Ko77 fibroblasts, the observed
changes had the same trends, but with minimal impacts (Figure
S7,D).
Changes in expression levels of CD64 influence the
inhibitory efficacy of infliximab
In order to confirm that Fc fragments of ADA and IFX indeed
modulate the efficacies of these drugs, we elevated the expression
of high affinity IgG receptor CD64 prior to treatments. To this
end, cells were pre-treated with IFN-c for 48 h, followed by short-
term incubation with anti-TNFs and treatment with TNF.
Consistently with the existing data for both monocytes [26] and
THP-1 cells [27], IFN-c treatment resulted in elevation of CD64
expression on both mRNA and protein levels (Figure 6A and
Figure S8, B). This was not the case for fibroblasts, probably due
to the fact that the receptor already overexpressed upon CMV
infection is less likely to further respond to cytokine treatment
(Figure S8,A). Interestingly, elevated levels of CD64 correlated
with a decrease in the efficacy of IFX in THP-1 cells (Figure 6B).
In contrast to THP-1 cells, treatment of Ko77 fibroblasts with
IFN-c did not change the efficacy IFX (Figure S8,F), most likely
due to the lack of its inducing effect on CD64 expression (Figure
S8,A and S8,E). This could be due to previously reported
suppressive effect of CMV on JAK/STAT pathway, which is
crucial for propagating IFN-c-induced responses [28]. This
phenomenon was specific only for CD64, since the mRNA
expression levels of other IFN-c target genes, such as ICAM-1,
were clearly induced upon treatment with this cytokine (Figure
S2,F and S8,C). To confirm whether CD64 is directly involved in
mediating inhibitory efficacy of IFX, we next suppressed the
expression of this receptor in THP-1 cells, before incubation with
anti-TNFs. Specific siRNAs were able to decrease the expression
of CD64 by 70% at the mRNA level (Figure 6C) and by 60% on
protein level (Figure S9,A). Although treatment with siRNA
improved the inhibitory efficacy of infliximab (Figure 6D), the
extent of this change was only moderate, possibly due to limited
effect of siRNA on the protein level. Another possibility would be
the lack of suppressing effect on the other CD64 isoforms, which
could be expressed in THP-1 cells, or because some other Fc
receptors, e.g. other isoforms of CD64 and/or CD16, may interact
with infliximab in our experimental set-up. To overcome these
limitations, we used phorbol-12-myristate-13-acetate (PMA), a
potent inducer of differentiation and a known modulator of the
CD64 expression in THP-1 cells [29]. As expected, we observed a
significant decrease in CD64 mRNA levels upon PMA-induced
differentiation (Figure 6E and Figure S9,B), which correlated with
an increase of macrophage-specific marker CD68 and another Fc
gamma receptor CD16 (Figure S9,C and S9,D). Consistently with
our working hypothesis, PMA-induced decrease of CD64 expres-
sion correlated with a complete recovery of the inhibitory efficacy
of infliximab, even at lower concentrations of the drug (Figure 6F).
High mRNA expression levels of Fc receptors in inflamed
colonic tissue correlate with the loss of response to
infliximab in IBD patients
To investigate the role of Fc receptors in the responsiveness
towards anti-TNF therapy we screened colonic biopsies of IFX
responders and non-responders together with the healthy control
subjects for the mRNA expression levels of various inflammatory
targets and Fc receptors (Figure 7). Endoscopic score was assessed
and presented in Figure 7A. The mRNA levels of all pro-
inflammatory targets were significantly higher in inflamed tissues
of IFX non-responders as compared to IFX responders, which was
consistent with the lack of the therapeutic response outcome
assessed by colonoscopy examination (Table S2 and Figure 7A).
Interestingly, the colonic mRNA levels of CD68 were not
significantly different between IFX responders and IFX non-
responders (Figure 7B), suggesting that increased infiltration of the
immune cells, such as macrophages, was not responsible for the
loss of response to IFX, which was suggested recently [16].
Strikingly, inflamed colonic biopsies from IFX non-responders
displayed significantly higher mRNA levels of all Fc gamma
receptors as compared to the non-inflamed tissues of IFX
responders (Figure 7C–E), along with relevant inflammatory
mediators (Figure 7F–L).
Discussion
In the present study we propose a new mechanism that
modulates the inhibitory efficacy of infliximab, which is dependent
on both its Fc fragment and the presence of high affinity Fc
gamma receptor CD64. We have demonstrated that IFX was
inefficient in cell types expressing CD64 including fibroblasts,
monocytic THP-1 cells and different subsets of immune cells
(PBMCs). We demonstrated that IFX was more potent in
activating CD64 by inducing the transcription of pro-inflamma-
tory genes, such as IL-8 and MCP-1. This was in striking contrast
Figure 2. Adalimumab and infliximab, but not certulizumab-pegol have limited efficacy in PBMCs. Peripheral blood of healthy donors
(n = 4) and IBD patients (n = 3) was treated with different anti-TNFs and subsequently with soluble TNF to induce pro-inflammatory responses in
PBMCs and plasma. The mRNA expression levels of CD64 (A), CD32 (B) and CD16 (C) Fc gamma receptors in healthy individuals and IBD patients were
assessed by RT-PCR as compared to THP-1 cells (set to 1). The extent of inhibition by each drug was determined by measuring mRNA levels of ICAM-1
(D), TNF (E), and IL-8 (F) after 2 h of TNF stimulation, as well as by the release of IL-8 after 24 h of combined TNF and anti-TNF stimulation (G). The
inhibitory efficacies were determined after eliminating intra-individual differences by setting the TNF-induced responses to 100% for each donor and
target (H–K). Error bars represent SEM. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0043361.g002
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to CZP, which blocks TNF, but lacks Fc region. Fab fragments of
IFX have statistically higher inhibitory efficacy, compared to the
whole IgG molecules and both blocking Fc parts of this drug and
changes in expression of CD64 correlate with the changes in its
Figure 3. Infliximab is more potent in activating Fc receptor CD64 than adalimumab. Both ADA and IFX immune complexes were added
to THP-1 cells to activate CD64 receptor in the presence (+FCS) or absence (2FCS) of serum. ADA/TNF complexes were more potent in inducing
phospho-tyrosine signaling (A), but IFX either alone or in complex with TNF induced phosphorylation of distinct tyrosine residues (enlarged insert,
right panel). Activation of CD64 downstream signaling leads to elevated transcription of GM-CSF (B, C), MCP-1 (D, E) and IL-8 (F, G) genes. Human
serum (HS) was used as a positive control for activation of Fc gamma receptor(s). Error bars represent SEM. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0043361.g003
Figure 4. Blocking of Fc receptors with IgG1 partially restores the efficacy of infliximab. CCD-18Co fibroblasts (A), Ko77 fibroblasts (C) and
THP-1 cells (E) were pre-incubated with human IgG1 isotype (10 mg/ml) prior to subsequent incubation with infliximab (1 mg/ml) and TNF (50 ng/ml).
Columns show mean values from a single, representative experiment measured in triplicates. Error bars indicate SD of three measurements. The
recovery of anti-TNF activity was also evaluated as percentage of inhibition of TNF-induced responses for each cell line (B, D, F).
doi:10.1371/journal.pone.0043361.g004
Anti-TNFs in Inflammatory Bowel Disease
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ability to block TNF-induced responses. Perhaps most important-
ly, we have shown that IFX non-responders express higher mRNA
levels of CD64 in their inflamed colonic tissues.
In agreement with our findings, it has been shown that ADA
and IFX bind to Fc receptor-expressing THP-1 cells in a manner
that is dependent on the addition of the human recombinant Fc
fragment [14]. At this point it cannot be excluded that binding of
IFX to Fc receptor(s) alone limits the ability of this drug to block
soluble TNF. Nevertheless, it is more likely that IFX-TNF
complexes, which form during neutralization of TNF, are
responsible for the limited anti-inflammatory effect via direct
activation of Fc receptor downstream signaling (Figure 8).
Adalimumab appears to have different mechanism in activating
Fc receptors as compared to infliximab and this seems to play role
in its overall anti-inflammatory outcome in THP-1 cells, but not
PBMCs (Figure 3 and Figure 2, respectively).
Our results imply that there are differences between tested anti-
TNF IgGs in their Fc fragments, which could be directly
responsible for the observed phenomena. Different glycosylation
patterns within Fc fragment might be responsible for the observed
differences in the efficacies between ADA and GOL (Figure 1 and
Figure S5). It is known that IFX contains more sialyl and core
fucose residues than ADA [30]. It can be anticipated that these
differences have direct consequences on the extent of the Fc
receptor(s) activation, which are expressed on the surface of the
implicated cell types, such as CMV-positive fibroblasts and
monocytes/macrophages (Figure 2). These and/or other glycal
residues could potentially translate to the clinical efficacy as
suggested elsewhere [31]. Removal of N-linked glycal residues did
not show any influence on the efficacy of ADA and IFX in our
experimental setup (Figure S10), suggesting that activation of
CD64 in our experimental setting is independent on the presence
of glycal residues linked to Fc region. In line with this notion,
binding to Fc receptors could lead to formation of large immune
complexes specific for different anti-TNFs and when bound to the
surface of cells expressing Fc receptor(s), it could in turn reduce the
diffusion of free anti-TNF IgG molecules and thereby limit the
amount of anti-TNF molecules capable of binding soluble TNF
and/or anti-TNFs engaged in ADCC. Either way, it can be
excluded that mTNF could be responsible for the observed
limitations of IFX, since we did not detect it in any of cell lines
used in the study (Figure S4, D). Despite this attractive hypothesis,
until now there are no studies supporting such mechanism and our
investigation is the first one, which, indicates that, this could be the
case.
Recently, it has been shown that certolizumab-pegol does not
show significant therapeutic efficacy as compared to placebo in a
large cohort of IBD patients indicating the importance of Fc
fragment in providing desired therapeutic effect [32]. Despite the
fact that we observe clear Fc-dependent negative effect of IFX in
our experimental system, at this point one cannot draw any
definite conclusions about which of the anti-TNFs would have
overall best therapeutic efficacy, since it greatly depends on many
factors, such as individual differences in biodistribution, state of
the disease and cell-drug interactions, which vary among IBD
patients. On the other hand, CZP induces a remission of the
disease in patients with elevated CRP levels. It is therefore
impossible to estimate if Fc fragment has a non-redundant role in
providing the therapeutic effect in all IBD patients.
Recently, CD64 has been implicated as a modulator of
responses against microbial challenge in the context of mucosal
inflammation in the intestine [33]. Additionally, CD64 and toll-
like receptor 4 have been reported to be up-regulated in CD
patients [34] and that this correlates with the clinical and
biological parameters of inflammation in patients with IBD [35].
These observations point out for the role of Fc receptors as
diagnostic markers and as potential modulating factors for
immunoglobulin-based drugs, similarly to what has been suggested
for abatacept and CD64 [36]. In line with these ideas, it has been
demonstrated that there is a correlation between the responsive-
ness towards infliximab and polymorphisms in the FcRIII receptor
isoforms [37,38]. Similar association was found in the case of
rheumatoid arthritis [39,40], which could support the current
hypothesis that Fc receptors can influence the outcome of IFX
therapy.
Interestingly, we observed a correlation between IFN-c-induced
CD64 expression and the loss of inhibitory efficacy of IFX in vitro
(Figure 6A and 6B). These data were strongly supported by the
fact that in contrast to IFX responders, inflamed tissues of IFX
non-responders express very high levels of IFN-c, which elevates
the expression levels of CD64 [26,27]. Strikingly, among all tested
target genes the most highly elevated cytokines in IFX non-
responders’ inflamed colonic tissues are the ones which are
generated upon binding to activating Fc gamma receptors (CD64
and CD16), namely GM-CSF, IL-6 and IL-8 (Figure 7). It is still
not clear whether increased expression levels of Fc gamma
Figure 5. Fc and Fab fragments of infliximab contribute
differently to its inhibitory efficacy. Blocking of Fc fragments of
adalimumab and infliximab changes their inhibitory efficacy in Ko77
fibroblasts (A). Graph shows mean values from four independent
experiments measured in triplicates. Error bars represent SD. Fab
fragments of anti-TNFs have different inhibitory efficacies as compared
to the whole IgG1 molecules in THP-1 cells (B). Columns represent mean
values of three independent experiments measured in triplicates and
set to 100 percent for TNF-treated cells. Error bars indicate SEM.
*p,0.05.
doi:10.1371/journal.pone.0043361.g005
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receptors detected in IFX non-responders are a cause or a
consequence of the lack of therapeutic effect of this drug.
Activation of Fc gamma receptors alone triggers the production
of MCP-1, IL-6 [41], and GM-CSF, which in turn leads to
generation of autoreactive T-cell responses [42]. As CD64 and
other Fc receptors are expressed by many immune cells, including
monocytes [43], most of the antigen-presenting cells and
phagocytic cells [44], the efficacy limitations may be relevant at
different sites of inflammation, such as blood, arthritic joints and
gastrointestinal tract. In support of this notion, it has been
reported that another Fc receptor, CD16, is elevated in IBD
monocytes [45,46], macrophages [47], and natural killer cells [48]
residing in the inflamed intestine. In line with our findings it may
indicate that monocytes and/or related cell types, such as dendritic
cells and macrophages, could be potential interacting partners for
IFX complexes and/or possibly other anti-TNF IgGs at sites of
inflammation. Elevated soluble forms of this receptor have been
detected in gut lavage fluid of IBD patients [49], which in turn
suggests that interaction between anti-TNF IgGs should attract
more attention with regard to possible consequences for the
therapy outcome.
In this study, we have also confirmed that intestinal fibroblasts
infected with CMV express relatively high amounts of high and
low affinity IgG receptors suggesting a correlation between CMV
Figure 6. Changes in expression levels of CD64 affect the efficacy of infliximab in THP-1 cells. Treatment with IFN-c elevates the mRNA
expression levels of CD64 (A), which result in the loss of efficacy of IFX and ADA (B). Decreased expression levels of CD64 (C) correlate with increased
inhibitory efficacy of IFX (D). PMA treatment decreases the expression levels of CD64 (E), which results in complete recovery of efficacy of IFX (F).
Graphs show mean values of at least three independent experiments measured in triplicates and columns are set to 100 percent for TNF-treated cells.
Error bars indicate SEM. *p,0.05.
doi:10.1371/journal.pone.0043361.g006
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infection and responsiveness towards IFX. Depending on the
subtype and the severity of the disease the occurrence of CMV
infection in the intestine of IBD patients varies between 6 and
64%, when determined using immunohistochemistry as a ‘golden
standard’ method of detection [50]. However at the same time
other studies indicate that the prevalence can vary greatly among
cohorts and could crucially depend on the detection method
[51,52]. CMV-induced FcR has strong preference to IgG1 as
compared to other IgG sub-classes [53]. In the context of these
findings, it has been recently demonstrated that the presence of
CMV is positively correlated with the loss of response to IFX in
IBD patients [54]. This observation was very supportive to our
data emphasizing the role of CD64 in the clinical efficacy of IFX
and possibly other anti-TNFs. Future studies will be needed to
evaluate the role of CD64 and potentially other Fc receptors in
modulating efficacy of anti-TNF drugs in more controlled clinical
setting thereby creating a perspective for personalized biological
therapy for IBD patients.
Materials and Methods
Ethics statement
Human intestinal biopsies and blood samples were collected at
the Clinic of Gastroenterology and Hepatology USZ in accor-
dance with the guidelines of ethical committee of Canton Zurich.
The committee specifically approved this study. Written consents
were taken from all the patients.
Patients’ samples
We analyzed biopsy specimens from 22 IBD patients (age 23–57
years), including 14 CD and 8 UC patients. Colonic biopsies were
taken from the sigmoid colon in all patients except one CD patient
Figure 7. Loss of response to infliximab correlates with increased levels of CD64 in IBD intestines. The level of intestinal inflammation
was assessed independently by endoscopic score and mRNA expression levels of pro-inflammatory target genes. The levels of Fc receptors were
assessed in colonic biopsies from IFX responders (n = 13) tissues and compared to IFX non-responders in both non-inflamed (n = 6) and inflamed
(n = 3) tissues. IL-18 mRNA was used as a specific negative control, since it is not elevated upon stimulation with pro-inflammatory cytokines (not
shown). The expression levels of each gene were normalized to those of a housekeeping gene b-actin. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0043361.g007
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in whom the sigmoid had been removed earlier after perforation.
Specimens were taken from either inflamed or non-inflamed
regions. Most IBD patients were immunosuppressed at the time of
colonoscopy (See Table S2). As control we analyzed biopsies from
sigmoid colon of healthy donors (age between 66 and 77), who
underwent surveillance colonoscopy after earlier polypectomy.
Detail description of patients’ characteristics is listed in Table S2.
Antibodies, Taqman assays, oligonucleotide primers and
other reagents
Human recombinant IFN-c (I3265), mouse monoclonal anti-
human b-actin antibody (A5441), DAPI (D9564) and PMA
(P1585) were purchased from Sigma-Aldrich (Buchs, Switzerland).
Recombinant TNF (C-63720) was from PromoCell/PromoKine
(Heidelberg, Germany). Human recombinant IL-1b (407615) was
purchased at Calbiochem-Merck Chemicals (Germany). Adalimu-
mab was from Abbott (Baar, Switzerland), infliximab from Essex
Chemie AG (Luzern, Switzerland), certolizumab-pegol from UCB
Pharma (Bulle, Switzerland), and golimumab from Centocor
Ortho Biotech Inc. (Horsham, PA). Mouse monoclonal anti-a-
smooth muscle actin (SMA) antibody (ab40865) was from Abcam
(Cambridge, UK), anti-villin antibody (MAB1639) from Chemi-
con (USA), and anti-CD16 (sc-70548), anti-CD32 (sc-53663), anti-
CD64 (sc-1184), anti-TNFR1 (sc-7895) and anti-fibronectin (sc-
9068) antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-CD64 antibody (3860-1) used for detection
of glycosylated band was obtained from Epitomics (Burlingame,
CA). Human IgG1 isotype control (ALX-804-133) was purchased
at Enzo Life Sciences (Plymouth Meeting, PA, USA). CCL2
(Hs00234240_m1), CSF2 (Hs00929873_m1), IL-1b
(Hs00174097_m1), IL-6 (Hs00174131_m1), IL-8
(Hs00174103_m1), ICAM-1 (Hs00164932_m1), CD68
(Hs00154355_m1), FCGR1A (Hs00174081_m1), FCGR2A
(Hs01017702_g1), FCGR3 (Hs00275547_m1), TNF
(Hs00174128_m1) and b-actin (4310881E) human gene expres-
sion assays were provided by Applied Biosystems (Foster City,
CA). For CMV detection we used primers specific for viral DNA
polymerase UL54 [55], which were purchased from Microsynth
(Balgach, Switzerland).
Cell lines
Caco2BBE, CCD-18Co, and THP-1 cell lines were cultivated at
37uC in a 5% CO2 incubator. Both Caco2BBE and CCD-18Co cell
lines were cultivated in high-glucose DMEM medium (Sigma-
Aldrich) containing L-glutamine, sodium bicarbonate, 10% FCS,
penicillin (100 U/ml) and streptomycin (100 mg/ml). THP-1 cells
were cultured in RPMI-1640 medium (Sigma-Aldrich) supple-
mented with 10% FCS, penicillin (100 U/ml) and streptomycin
Figure 8. Schematic representation of the working model. IFN-c induces its receptor downstream signaling involving JAK and STAT proteins
(A). STAT dimers elevate the transcription of the CD64 (FCGR1) gene (B). Translated CD64 protein is targeted into plasma membrane, where it resides
in an inactive state until binding immune complexes IFX-TNF (C). Propagation of downstream signaling (D) occurs through immunoreceptor tyrosine-
based activation motif (ITAM) leading to the transcription of relevant target genes (E) via parallel activation of p38, JNK and ERK kinases [58].
Production and release of IL-8 and other pro-inflammatory factors contribute to the limited outcome of IFX treatment.
doi:10.1371/journal.pone.0043361.g008
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(100 mg/ml). All cell lines were purchased from ATCC-LGC
Promochem (Molsheim Cedex, France). Ko77, F141, F148, and
F188 fibroblasts were isolated and cultivated as described
elsewhere [56].
Cytokine treatments and incubations with anti-TNF
therapeutic antibodies
Cell lines were incubated with pro-inflammatory cytokines
TNF, IL-1b, and IFN-c at the concentration of 50 ng/ml.
Concentrations of the anti-TNF IgG1s used in the experiments
were 10 mg/ml (adalimumab, infliximab and golimumab) and
24 mg/ml for certolizumab-pegol. For inhibition experiments cells
were pre-incubated with anti-TNF therapeutics for 60 min at
37uC prior to treatment with TNF (50 ng/ml) for another 60 min.
RNA isolation, cDNA synthesis, and real-time PCR
RNA was isolated with QIAcube (QIAGEN, Hombrechtikon,
Switzerland) using the protocol for animal cell isolation with
DNAse digest, or alternatively using TRIzol reagent (Invitrogen,
Zug, Switzerland). The amount and quality of RNAs were
determined using ND-1000 spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE). Complementary DNAs were produced
using High Capacity cDNA Reverse Transcription Kit (4368814,
Applied Biosystems). Real-time PCR reactions containing 10 ml of
Fast Universal Master Mix (Applied Biosystems) and 1 ml of a
TaqMan gene expression assay (Applied Biosystems) in 20 ml of
total volume. The cycle conditions were: stage 1 (50uC, 2 min);
stage 2 (95uC, 10 min); stage 3: 40 repeats (95uC, 15 s; 60uC,
1 min). The expression levels of the target genes were normalized
to the expression levels of b-actin using the comparative threshold
cycle method.
Protein concentration determination
Protein concentrations were determined using the BCA Protein
Assay Reagent (Pierce, Wohlen, Switzerland).
SDS electrophoresis and Western blotting
Protein electrophoresis was performed according to the
standard protocol. Briefly, proteins were separated in 10%
polyacrylamide gels (Tris/glycine) and transferred onto nitrocel-
lulose membranes. For Western blotting, membranes were
blocked with 5% solution of non-fat dried milk buffer in TBS-T
(TBS+0.1%Tween) for 1 h at RT with gentle shaking. Primary
antibodies were diluted in TBS-T containing 5% BSA and
incubated with the membranes overnight at 4Cu. Corresponding
secondary antibodies were diluted in TBS-T buffer containing 5%
blocking milk for 1 h at RT. Bands were detected by using ECL
detection kit (GE Healthcare, Glattbrugg, Switzerland) and
autoradiography. Densitometry analysis of the protein bands was
performed using OptiQuant software.
Immunofluorescence microscopy
CCD-18Co cells were plated onto sterile glass coverslips and
cultured until full confluence. Prior to their fixation cells were
washed once with PBS and fixed with 3.7% solution of
formaldehyde for 30 min at RT. After washing three times with
PBS, cells were permeabilized with 0.25% Triton X-100 for
15 min at RT prior to incubation with blocking solution (1% of
bovine serum albumin (BSA) in PBS) for 1 h at RT, and
subsequently with anti-fibronectin and anti-CD64 antibodies
overnight at 4uC. Coverslips were incubated with corresponding
secondary anti-rabbit Cy2 and anti-mouse Cy3 antibodies diluted
in blocking solution. Samples were mounted using anti-fade
mounting medium (DAKO, Glostrup, Denmark) and analyzed by
fluorescence microscopy (Zeiss, Oberkochen, Germany).
Incubation of peripheral blood with anti-TNFs and
isolation of PBMCs
Fresh human peripheral blood (40 ml) was divided into eight
parts for treatment with anti-TNFs and soluble TNF according to
the protocol used for cell lines (see above). PBMCs were isolated in
according to standard Ficoll (GE Healthcare) protocol. Briefly,
diluted blood was overlayed onto Ficoll and centrifuged at
1700 rpm for 40 min. PBMCs from interphase were collected,
washed once with PBS+0.1% BSA and harvested for RNA
extraction. Detail description of blood samples from both healthy
donors and IBD patients used for this set-up is listed in Table S1.
Formation of anti-TNF/TNF immune complexes
Complexes of ADA or IFX and TNF were formed by
incubation at 37uC for 30 min in PBS prior to addition to cells.
The ratio of anti-TNFs (100 mg/ml) vs soluble TNF (500 ng/ml)
was the same as for stimulation experiments (see above).
Blocking of Fc fragments of therapeutic antibodies
Adalimumab and infliximab were incubated with protein A
sepharose beads (GE Healthcare) for 30 min at RT prior to
incubation with fibroblasts for 30 min at 37uC. Afterwards, the
cells were treated with TNF for 1 h, harvested and processed for
RNA isolation.
Proteolytic digestion and deglycosylation of therapeutic
antibodies
Adalimumab and infliximab were digested by IdeS endopep-
tidase as described elsewhere [57]. Anti-TNFs were incubated with
IdeS (FabRICATORH, Synovis, Sweden) according to manufac-
turer’s protocol and processed for protein chip analysis (Agilent
Technologies, USA). Purified Fab9 fragments were obtained by
removing Fc fragments from the reaction mixture using protein A
sepharose beads according to the manufacturer’s protocol
(General Healthcare, UK). Deglycosylation of anti-TNFs was
performed using recombinant glycosidase (IgZEROH, Synovis,
Sweden) according to manufacturer’s protocol.
SiRNA transfections
Transient downregulation of CD64 expression in THP-1 cells
was achieved using NucleofectorH kit V (Amaxa, USA). Specifi-
cally, 106 cells per condition were suspended in 100 ml of
NucleofectorH solution and 6 ml of 50 mM siRNA mix containing
three different siRNA sequences: s5069, s5068, and s230564
(Applied Biosystems/Ambion, USA) were added for 10 min at
RT. Next, the samples were subjected to nucleofection using high
viability protocol (V001) and grown in standard medium for 3
days.
Statistical analysis
Statistical significance was determined by performing either
ANOVA analysis with Tukey’s multicomparison post-test or two-
tailed paired t-test using Graph Pad Prism 5 software (GraphPad
Software, La Jolla, CA).
Supporting Information
Figure S1 Ko77 and CCD-18Co fibroblast are CMV-
positive. (A) Real-time PCR amplification curves show the
expression of viral UL54 mRNA in both fibroblastic cell lines used
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in the study. The specificity of the PCR products was confirmed by
the kinetics of dissociation curves for b-actin (B) and UL54 (C).
(TIF)
Figure S2 Intestinal epithelial cells, intestinal myofi-
broblasts and monocyte-macrophage cells can be effi-
ciently treated with inflammatory cytokines to induce
inflammatory responses. Caco2BBE (A–C), CCD-18Co (D–F)
and THP-1 (G–I) cell lines were treated with three different
cytokines to induce pro-inflammatory responses. Cells were
harvested at different time points to monitor the kinetics of
mRNA production of different genes. Values on Y-axis represent
mRNA expression levels relative to ß-actin. Columns represent the
mean values of three measurements within a single, representative
experiment. Error bars represent SD.
(TIF)
Figure S3 Pro-inflammatory cytokines trigger specific
signaling pathways in the cell lines used in the study. (A)
IFN-c, but neither TNF nor IL-1b, induces phosphorylation of
STAT1 in intestinal epithelial Caco2BBE cells. (B) TNF induces
phosphorylation of CREB, ATF-1 and p38 MAPK proteins in
intestine-derived fibroblasts CCD-18Co. (C) TNF, but not IFN-c,
activates NF-kB in Caco2BBE cells as measured by electrophoretic
mobility shift assay. Cells were treated with two different pro-
inflammatory cytokines to test the specificity of the binding to the
NF-kB-specific radiolabelled probe. Maximum activation was
observed after 60 min. Addition of anti-p65 antibodies shifts the
size of the protein-DNA complexes towards higher molecular
weight, showing the specificity of the protein binding to the probe.
(D) IL-1b activates NF-kB in Caco2BBE cells as measured by
EMSA. Maximum activation was observed after 30 min. All
cytokines were used at the concentration of 50 ng/ml.
(TIF)
Figure S4 Infliximab has limited efficacy in fibroblasts
isolated from CD patients. (A) Fibroblasts isolated from CD
patient (MC153) and (B) isolated from fistulizing CD patient
(F188) were incubated with either adalimumab or infliximab
before treatment with TNF. Columns represent the mean values of
three measurements within a single, representative experiment
relative to ß-actin. Error bars represent SD. Caco2BBE cells,
intestinal fibroblasts and THP-1 cells express Fc receptors (C), but
not mTNF (D). Recombinant TNF was used as a positive control
(17 kDa). M: Molecular weight marker.
(TIF)
Figure S5 Golimumab displays reduced inhibitory
efficacies in intestinal fibroblasts and THP-1 cells, but
not in intestinal epithelial Caco2BBE cell line. (A) THP-1
cells (B) Caco2BBE, (C) Ko77, and (D) CCD-18Co cells were pre-
incubated with golimumab and subsequently treated with TNF.
The graphs show the results of a single experiment, measured in
triplicates. Error bars represent SD.
(TIF)
Figure S6 Human serum changes the efficacy of IFX on
fibroblasts and monocytes. (A) CCD-18Co fibroblasts were
pre-incubated with human serum for 30 min prior to treatment
with anti-TNF therapeutics and TNF. Graph shows result of a
single experiment measured in triplicate. Error bars indicate SD of
three measurements. (B) Quantification of TNF inhibition by
infliximab in CCD-18Co fibroblasts expressed as percentage. (C)
THP-1 cells were pre-incubated with human serum for 30 min
prior to treatment with anti-TNF therapeutics and TNF. Graph
shows result of single experiment measured in triplicates. Error
bars indicate SD of three measurements. (D) Quantification of
TNF-induced response inhibition by infliximab in THP-1 cells
expressed as percentage. Graphs show the results of single
experiment measured in triplicates.
(TIF)
Figure S7 Blocking of Fc and isolation of Fab fragments
can be successfully applied for testing the efficacies of
anti-TNFs. (A) Both adalimumab and infliximab, but not
certolizumab-pegol bind to protein A sepharose beads. (B) Fab
and Fc fragments can be produced by incubation with
recombinant immunoglobulin-degrading enzyme of Streptococcus
(IdeS, FabRICATORH). (C) After proteolytic digestion Fab
fragments of ADA and IFX were removed from the reaction
mixture by immunoprecipitation using protein A sepharose beads.
(D) Ko77 fibroblasts were pre-treated with either intact IgG1
molecules or Fc-purified digestion mixture containing Fab9
fragments of ADA or IFX and subsequently stimulated with
TNF. The percentage of TNF inhibition was assessed based on the
production of TNF mRNA by RT-PCR.
(TIF)
Figure S8 IFN-c does not induce CD64 mRNA expres-
sion and does not influence inhibitory efficacy of IFX in
Ko77 fibroblasts. mRNA expression levels of CD64 in Ko77
fibroblasts (A) and THP-1 cells (B) upon IFN-c treatment. IFN-c-
induced progressive elevation of ICAM-1 mRNA levels in Ko77
(C), which was similar to the effect observed for CCD-18Co
fibroblasts (Figure S2,F). (D) mRNA levels of CD64 in Ko77 cells
after 48 hours of IFN-c treatment. (E) Protein levels of CD64 in
Ko77 and THP-1 cells after 48 hours of IFN-c treatment. (F) Pre-
incubation with IFN-c had no impact on inhibitory efficacy of IFX
in Ko77 fibroblasts. The graph shows results from a single
experiment measured in triplicates. Error bars indicate SD of
triplicates.
(TIF)
Figure S9 The expression levels of CD64 can be
decreased by either siRNA or PMA treatment in THP-1
cells. (A) Western blot analysis of CD64 in pGFP- and siRNA-
transfected cells. The mRNA expression levels of CD64 (B),
macrophage-specific marker CD68 (C) and CD16 (D) analyzed
48 h after the treatment with different amounts of PMA. The
graphs show results from a single representative experiment
measured in triplicates. Error bars indicate SD of triplicates.
(TIF)
Figure S10 Glycosylation at Asn297 does not influence
the inhibitory efficacy of anti-TNF therapeutic antibod-
ies. (A) Both adalimumab and infliximab were deglycosylated at
Asn297 as indicated by the shift in molecular mass in SDS-PAGE
and Coomassie staining. This modification did not result in
significant change in the inhibitory efficacy of anti-TNF antibodies
in either Ko77 fibroblasts (B) or in monocytic THP-1 cells (C). The
graphs show results from a single experiment measured in
triplicate. Error bars indicate SD of triplicates. ADA(d): de-
glycosylated adalimumab; IFX(d): de-glycosylated infliximab.
(TIF)
Table S1 Basic characteristics of peripheral blood
donors used in the study. 5-ASA: 5-aminosalicylic acid,
IFX: infliximab.
(TIF)
Table S2 Basic description of human intestinal speci-
mens used in the study. 5-ASA: 5-aminosalicylic acid; IFX:
infliximab; ADA: adalimumab; ABA: abatacept; VED: vedolizu-
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mab; MTX: methotrexate; CZP: certolizumab-pegol; nd: not
determined; N/A: not applicable.
(TIF)
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